Abbott Laboratories (ABT) to Release Quarterly Earnings on Wednesday

Abbott Laboratories (NYSE:ABT - Get Free Report) is expected to be announcing its earnings data before the market opens on Wednesday, January 22nd. Analysts expect the company to announce earnings of $1.34 per share and revenue of $11,029,400.00 billion for the quarter. Investors that are interested in registering for the company's conference call can do so using this link.

Abbott Laboratories Stock Down 0.4 %

Shares of NYSE ABT traded down $0.46 during trading hours on Monday, hitting $113.45. The company had a trading volume of 6,443,213 shares, compared to its average volume of 4,199,178. The stock has a market capitalization of $196.78 billion, a P/E ratio of 34.48, a price-to-earnings-growth ratio of 2.40 and a beta of 0.73. The company has a quick ratio of 1.14, a current ratio of 1.60 and a debt-to-equity ratio of 0.32. The firm's 50 day moving average is $114.93 and its 200-day moving average is $112.87. Abbott Laboratories has a 1-year low of $99.71 and a 1-year high of $121.64.

Abbott Laboratories Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Wednesday, January 15th will be paid a dividend of $0.59 per share. The ex-dividend date of this dividend is Wednesday, January 15th. This is a positive change from Abbott Laboratories's previous quarterly dividend of $0.55. This represents a $2.36 annualized dividend and a dividend yield of 2.08%. Abbott Laboratories's payout ratio is currently 66.87%.

Wall Street Analysts Forecast Growth

ABT has been the topic of a number of research analyst reports. Piper Sandler increased their price target on Abbott Laboratories from $131.00 to $133.00 and gave the company an "overweight" rating in a research note on Thursday, October 17th. Evercore ISI increased their target price on Abbott Laboratories to $136.00 and gave the stock a "buy" rating in a research note on Thursday, January 2nd. Sanford C. Bernstein boosted their price target on Abbott Laboratories from $133.00 to $138.00 and gave the company an "outperform" rating in a research note on Thursday, October 17th. Barclays lifted their target price on Abbott Laboratories from $143.00 to $149.00 and gave the stock an "overweight" rating in a report on Tuesday, November 5th. Finally, Raymond James reaffirmed a "buy" rating and set a $129.00 price target (up from $122.00) on shares of Abbott Laboratories in a research report on Monday, October 14th. Four investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $131.57.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.